FNY Investment Advisers’s Galectin Therapeutics GALT Stock Holding History

FNY Investment Advisers’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-600	Closed	–	–	1033
2025 Q1	$0	Buy	+600	New	+$842	﹤0.01%	814

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FNY Investment Advisers's GALT Position: Q2 2025 in Review

FNY Investment Advisers sold out of Galectin Therapeutics (GALT) in Q2 2025, closing a stake of 600 shares.

FNY Investment Advisers first reported a position in GALT in Q1 2025 and held it in 1 quarter. The position peaked at $0 in Q1 2025. 86 funds tracked by Wall St. Rank hold GALT as of Q2 2025.

FNY Investment Advisers reported no remaining Galectin Therapeutics position as of Q2 2025 after selling out during the quarter.
FNY Investment Advisers sold 600 Galectin Therapeutics shares in Q2 2025.
FNY Investment Advisers first reported a position in Galectin Therapeutics in Q1 2025 and held it in 1 quarter.
FNY Investment Advisers's Galectin Therapeutics position peaked at $0 in Q1 2025.
86 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2025.

Based on FNY Investment Advisers's 13F filing for Q2 2025, filed 30 Jul 2025.